Surgical considerations for invasive breast cancer

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Treatment

Background:

• The 1992 NIH Consensus Development Conference established breast-conserving surgery (BCS) as a primary therapy for early-stage breast cancer.
• Subsequent clinical trials have consistently validated BCS's efficacy, demonstrating survival rates equivalent to mastectomy.
• Uneven adoption of BCS suggests surgeon-related barriers, including personal comfort and patient communication.

Purpose of the Study:

• To review the evidence supporting breast-conserving surgery (BCS) for early-stage breast cancer.
• To discuss patient selection criteria for BCS versus mastectomy.
• To emphasize the importance of achieving negative margins and appropriate local control in BCS.

Main Methods:

• Review of prospective clinical trials and consensus conference reports on breast cancer treatment.
• Analysis of outcomes for BCS, mastectomy, and neoadjuvant chemotherapy.
• Evaluation of factors influencing treatment decisions, including tumor size, stage, and cosmetic outcomes.

Main Results:

• BCS provides survival outcomes comparable to mastectomy for stage I and II breast cancer.
• Mastectomy is appropriate when BCS cannot achieve tumor control, even after revisions.
• Preoperative chemotherapy enables successful excision for larger tumors with good local and distant control.
• Very large tumors may require primary chemotherapy, as they often represent more advanced disease.

Conclusions:

• BCS is a safe and effective primary treatment for most early-stage breast cancer patients.
• Surgeons must balance cosmetic considerations with the oncologic imperative of achieving pathologically negative margins.
• Optimal initial surgical control is crucial to prevent local recurrence and the need for salvage mastectomy.